SG227 / Sana Biotech - LARVOL DELTA

Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs (GlobeNewswire) - "The data were reported in an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting....'Data presented at ASGCT highlight the fusogen platform’s potential to enable development of therapies that offer off-the-shelf treatment options for patients with blood cancers, B cell-mediated autoimmune disorders, and multiple myeloma. The data support our strategy of advancing SG293 into the clinic for the treatment of non-Hodgkin lymphoma (NHL) later this year and SG227, a BCMA-targeted in vivo CAR T cell therapy, into the clinic for the treatment of multiple myeloma as early as mid-2027'."

New trial • Preclinical • Immunology • Multiple Myeloma • Non-Hodgkin’s Lymphoma